PFS
SAGE

Prospera Financial Services’s Sage Therapeutics SAGE Stock Holding History

Prospera Financial Services’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-250
Closed -$8K – 2416
2022
Q1 		$8K Buy
+250
New +$9.4K ﹤0.01% 2136
2020
Q4 		– Sell
-1,118
Closed -$68K – 1388
2020
Q3 		$68K Buy
+1,118
New +$56.7K 0.03% 523

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Prospera Financial Services's SAGE Position: Q2 2022 in Review

Prospera Financial Services sold out of Sage Therapeutics (SAGE) in Q2 2022, closing a stake of 250 shares — an estimated $8K sold.

Prospera Financial Services first reported a position in SAGE in Q3 2020 and held it in 2 quarters. The position peaked at $68K in Q3 2020. 209 funds tracked by Wall St. Rank hold SAGE as of Q2 2022.

  • Prospera Financial Services reported no remaining Sage Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Prospera Financial Services sold 250 Sage Therapeutics shares in Q2 2022, an estimated $8K.
  • Prospera Financial Services first reported a position in Sage Therapeutics in Q3 2020 and held it in 2 quarters.
  • Prospera Financial Services's Sage Therapeutics position peaked at $68K in Q3 2020.
  • 209 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2022.

Based on Prospera Financial Services's 13F filing for Q2 2022, filed 8 Aug 2022.